CPT code 20701 denotes removal of a previously placed drug delivery device from subfascial tissues with layered closure when billed in addition to a separate primary procedure. This procedure-level code is important nationally because it distinguishes a discrete surgical explant performed concurrently with another operative service, affecting billing, coding compliance, and payment bundling decisions. Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will gain a concise overview of the clinical context for explanting subfascial drug delivery devices, how CPT code 20701 is used in conjunction with primary procedural codes, and where this service is typically provided (operating room or surgical suite). The publication also summarizes common modifiers relevant to concurrent procedures, payer coverage considerations, and typical billing scenarios to help revenue cycle, coding, and policy teams interpret claims reporting. Data not available in the input will be noted where applicable.